Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Severe blood pressure (BP) fluctuation happens during surgery for pheochromocytoma and paraganglioma (PPGL) due to the release of catecholamines. 131 I MIBG scintigraphy indicates the capacity of PPGL to retake and reserve catecholamines. This study aims to utilize 131 I MIBG scintigraphy to predict intraoperative BP fluctuation in patients undergoing PPGL surgery, thereby guiding preoperative preparation.

Methods: This study included 159 patients receiving 131 I MIBG scintigraphy before surgery for PPGL. Uptake of 131 I MIBG was assessed with an MIBG score ranging from 2 to 8. Factors that may be related to hemodynamic stability were collected. BP fluctuation was evaluated by systolic blood pressure average real variability (SBP ARV) and mean arterial pressure average real variability (MAP ARV).

Results: One hundred fifty-nine consecutive patients with PPGL were included in this study. Patients with an MIBG score of 2 (10.3±4.6 mm Hg) had lower SBP ARV than patients with a score of 5 (14.9±5.6 mm Hg, p =0.012), score of 7 (13.8±5.0 mm Hg, p =0.013) and score of 8 (14.7±7.3 mm Hg, p =0.007). Patients with 131 I MIBG score of 2 (7.6±3.2 mm Hg) also had a lower MAP ARV than patients with a score of 5 (10.3±4.3 mm Hg, p =0.045) and a score of 8 (9.8±4.5 mm Hg, p =0.029). In multiple linear regression analyses, MIBG score ( p =0.010), metanephrine ( p =0.014), and maximum preoperative blood pressure ( p =0.021) were correlated with SBP ARV.

Conclusions: Preoperative 131 I MIBG scintigraphy is associated with intraoperative BP fluctuation in patients with PPGL. Metanephrine, maximum preoperative blood pressure, and 131 I MIBG scintigraphy can predict intraoperative BP fluctuation independently. Personalized preoperative management can be offered to patients based on these assessments.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000006042DOI Listing

Publication Analysis

Top Keywords

131 mibg
32
mibg scintigraphy
24
blood pressure
20
mibg score
16
fluctuation patients
12
intraoperative fluctuation
12
mibg
11
patients
10
score
9
pressure fluctuation
8

Similar Publications

[F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.

Eur J Nucl Med Mol Imaging

July 2025

Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China.

Purpose: [F]-meta-fluorobenzylguanidine ([F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma, however, their respective clinical roles remain unclear. This prospective study compared [F]MFBG PET with SSTR-targeted PET, using either [Ga]Ga-DOTATATE or [F]AlF-NOTA-octreotide([F]-OC), to evaluate diagnostic performance and potential clinical impact in neuroblastoma.

Methods: Sixteen patients (median age 5.

View Article and Find Full Text PDF

Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor-positive PPGLs and has shown promising efficacy and generally mild toxicity. However, rare instances of fatal crises following treatment have been reported.

View Article and Find Full Text PDF

High specific-activity I-metaiodobenzylguanidine ([I]MIBG) therapy is approved for patients with pheochromocytoma or paraganglioma. As [I]MIBG is not effectively cleared through dialysis, the 2008 European Association of Nuclear Medicine guidelines list renal insufficiency requiring dialysis as a contraindication for [I]MIBG treatment. We describe the clinical and dosimetry findings of a hemodialysis-dependent patient with metastatic paraganglioma who was treated with [I]MIBG.

View Article and Find Full Text PDF

Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine.

J Radiat Res

July 2025

Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.

The rare abscopal effect in radiotherapy is thought to result from immune-activating damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), released from cancer cells. While external irradiation of cancer cells increases HMGB1 release, it remains unclear whether internal radiotherapy with 131I-meta-iodobenzylguanidine (131I-MIBG) induces similar effects. This study aimed to determine if HMGB1 is released from human-derived cancer and normal cells after 131I-MIBG administration.

View Article and Find Full Text PDF

Objective: Severe blood pressure (BP) fluctuation happens during surgery for pheochromocytoma and paraganglioma (PPGL) due to the release of catecholamines. 131 I MIBG scintigraphy indicates the capacity of PPGL to retake and reserve catecholamines. This study aims to utilize 131 I MIBG scintigraphy to predict intraoperative BP fluctuation in patients undergoing PPGL surgery, thereby guiding preoperative preparation.

View Article and Find Full Text PDF